HCW Biologics (HCWB) Price & Analysis

Compare

184 Followers

HCWB Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.77 - $100.80

Previous CloseN/A

Volume102.01K

Average Volume (3M)3.89M

Market Cap

$8.26M

Enterprise Value$13.16M

Total Cash (Recent Filing)$1.11M

Total Debt (Recent Filing)$6.23M

Price to Earnings (P/E)―

Beta0.94

Next Earnings

Nov 05, 2025

EPS Estimate

1.58

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-6.79

Shares Outstanding2,151,607

10 Day Avg. Volume115,605

30 Day Avg. Volume3,893,769

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.59

Enterprise Value/Revenue9.10

Enterprise Value/Gross Profit38.06

Enterprise Value/Ebitda-0.57

Forecast

1Y Price Target

$35.00

Price Target Upside845.95% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentHCW Biologics announced the selection of a lead candidate for clinical development, HCW11-040, from the next-generation checkpoint inhibitor program of its TRBC platform.

EarningsThe potential $7M upfront from Wy Biotech could fund the company into mid-2026.

Bears Say

Financial PerformanceHCW Biologics has received further communication from WY Biotech that it is not likely to meet the amended payment deadline.

HCW Biologics News

HCW Biologics congratulates Wugen on equity financing

HCW Biologics (HCWB) congratulates Wugen on its recently announced $115M equity financing led by Fidelity Management & Research...

14d ago

HCWB

HCW Biologics announces results from second-gen T-cell engager programs

HCW Biologics (HCWB) announced that its scientists have successfully developed second-generation, tissue factor-targeting T-cell engagers against solid tumors,...

24d ago

HCWB

HCW Biologics’ Innovative Lead Candidate HCW11-040 Boosts Cancer Therapy Potential

Analyst Michael Okunewitch of Maxim Group maintained a Buy rating on HCW Biologics, retaining the price target of...

15d ago

HCWB

HCW Biologics Extends License Fee Payment Deadline

HCW Biologics ( ($HCWB) ) has issued an announcement. HCW Biologics Inc. and WY Biotech Co., Ltd. have...

27d ago

HCWB

HCW Biologics Stock Rockets 55% on Cancer Treatment Data

HCW Biologics stock rocketed on Monday after the company announced results from its new cancer treatment. ...

1M ago

HCWB

Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!

Stocks are active today with analysts updates, clinical trials, earnings reports, and more. ...

1M ago

HCW Biologics develops second-generation immune checkpoint inhibitor

HCW Biologics (HCWB) announced that its scientists have developed second-generation, pembrolizumab-based immunotherapeutics against solid tumors, particularly for pancreatic...

1M ago

HCWB

HCW Biologics Faces Nasdaq Non-Compliance Notice

HCW Biologics ( ($HCWB) ) has provided an announcement. On June 26, 2025, HCW Biologics Inc. announced that...

1M ago

HCWB

HCW Biologics Delays Q2 10-Q Filing

HCW Biologics ( ($HCWB) ) has released a notification of late filing. HCW Biologics Inc. has announced a...

2M ago

HCWB

HCW Biologics Amends Equity Purchase Agreement

HCW Biologics ( ($HCWB) ) has shared an announcement. On August 14, 2025, HCW Biologics Inc. and Square...

2M ago

HCWB

HCW Biologics Secures $7M License Fee Agreement

HCW Biologics ( ($HCWB) ) has provided an update. On May 29, 2025, WY Biotech Co., Ltd. completed...

3M ago

HCWB

HCW Biologics Advances Alopecia Areata Treatment with New Phase 1 Study

Hcw Biologics, Inc. (($HCWB)) announced an update on their ongoing clinical study. HCW Biologics, Inc. is initiating a...

3M ago

HCWB

HCW Biologics Completes Warrant Exercise with Armistice

HCW Biologics ( ($HCWB) ) has issued an announcement. On May 13, 2025, HCW Biologics Inc. entered into...

3M ago

HCWB

HCW Biologics regains compliance with Nasdaq Capital Market requirements

HCW Biologics (HCWB) has received notice from The Nasdaq Stock Market informing the Company that it has regained...

3M ago

HCWB

HCWB FAQ

What was HCW Biologics’s price range in the past 12 months?

HCW Biologics lowest stock price was $2.77 and its highest was $100.80 in the past 12 months.

What is HCW Biologics’s market cap?

HCW Biologics’s market cap is $8.26M.

When is HCW Biologics’s upcoming earnings report date?

HCW Biologics’s upcoming earnings report date is Nov 05, 2025 which is in 33 days.

How were HCW Biologics’s earnings last quarter?

HCW Biologics released its earnings results on Aug 18, 2025. The company reported -$6.79 earnings per share for the quarter, missing the consensus estimate of $1.8 by -$8.59.

Is HCW Biologics overvalued?

According to Wall Street analysts HCW Biologics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does HCW Biologics pay dividends?

HCW Biologics does not currently pay dividends.

What is HCW Biologics’s EPS estimate?

HCW Biologics’s EPS estimate is 1.58.

How many shares outstanding does HCW Biologics have?

HCW Biologics has 2,151,607 shares outstanding.

What happened to HCW Biologics’s price movement after its last earnings report?

HCW Biologics reported an EPS of -$6.79 in its last earnings report, missing expectations of $1.8. Following the earnings report the stock price went down -1.711%.

Which hedge fund is a major shareholder of HCW Biologics?

Currently, no hedge funds are holding shares in HCWB

HCW Biologics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-9999.00%

Trailing 12-Months

Asset Growth

7.79%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

HCW Biologics

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

HCW Biologics (HCWB) Earnings & Revenues

Historic Earnings Reports

HCWB Stock 12 Month Forecast

Average Price Target

$35.00

▲(845.95% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","67":"$67","18.25":"$18.25","34.5":"$34.5","50.75":"$50.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$35.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,18.25,34.5,50.75,67],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Feb<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.35,7.63076923076923,9.911538461538461,12.192307692307692,14.473076923076922,16.753846153846155,19.034615384615385,21.315384615384616,23.596153846153847,25.876923076923077,28.157692307692308,30.43846153846154,32.71923076923077,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.35,7.63076923076923,9.911538461538461,12.192307692307692,14.473076923076922,16.753846153846155,19.034615384615385,21.315384615384616,23.596153846153847,25.876923076923077,28.157692307692308,30.43846153846154,32.71923076923077,{"y":35,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.35,7.63076923076923,9.911538461538461,12.192307692307692,14.473076923076922,16.753846153846155,19.034615384615385,21.315384615384616,23.596153846153847,25.876923076923077,28.157692307692308,30.43846153846154,32.71923076923077,{"y":35,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":63.6,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.07,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.2,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":17.84,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":11.13,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":11.24,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.73,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.21,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.75,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.35,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >